RxDoctor Payments Data

Roy Anderson

Family · Schertz, TXNPI 1609489533

Payments from drug & device makers

$1,576in general payments, 2019–2025

Across 92 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$426
  • Novo Nordisk$208
  • Bayer$126
  • Globus Medical$121
  • Exact Sciences$121
  • Cardiva Medical, Inc.$119
  • plus $456 from 10 others

What the payments were for

  • Food & beverage$1,576100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,576 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$165,055
Medicare patients
265
Services billed
2,906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol87$102,670
XareltoRivaroxaban58$59,785
EliquisApixaban45$53,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$46,915
TrulicityDulaglutide25$46,720
Diclofenac Potassium12$41,366
JardianceEmpagliflozin34$40,063
OzempicSemaglutide35$38,719
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate11$37,715
Tresiba Flextouch U-200Insulin Degludec24$31,723
Chlorzoxazone15$30,450
EntrestoSacubitril/Valsartan13$21,042
JanuviaSitagliptin Phosphate16$18,671
Methocarbamol22$12,826
MounjaroTirzepatide12$12,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$96$102,67087 claims
Lilly USA, LLCTrulicity, Mounjaro$102$59,00937 claims
GSKTrelegy Ellipta, Anoro Ellipta$19$54,67553 claims
PfizerEliquis$53$53,62545 claims
Novo NordiskOzempic$208$38,71935 claims
MerckJanuvia$18$18,67116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.

Other family in Schertz

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →